| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | TKR; TKT2 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human TKTL1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于TKTL1抗体的3篇参考文献概览，涵盖不同研究方向：
---
1. **文献名称**: *TKTL1 is overexpressed in a large portion of human tumors and promotes tumor growth and progression in vivo*
**作者**: Xu et al.
**摘要**: 该研究通过免疫组化(使用TKTL1特异性抗体)分析了多种癌症组织中TKTL1蛋白的表达水平，发现其在结直肠癌、乳腺癌等肿瘤中显著高表达。实验表明，抑制TKTL1可降低癌细胞糖酵解活性和体内成瘤能力，提示其作为治疗靶点的潜力。
---
2. **文献名称**: *Monoclonal antibody against TKTL1 catalyzed NADPH synthesis and predicts poor prognosis in human gliomas*
**作者**: Zhang et al.
**摘要**: 研究团队开发了一种针对TKTL1的单克隆抗体，验证其特异性后用于胶质瘤组织检测。结果显示，TKTL1高表达与患者总生存期缩短相关，且通过促进NADPH合成增强癌细胞氧化应激抵抗能力，为预后评估提供了新标志物。
---
3. **文献名称**: *TKTL1 as a target for antibody-mediated therapy in hypoxic tumors*
**作者**: Coy et al.
**摘要**: 该文献利用TKTL1抗体研究其在肿瘤缺氧微环境中的功能，发现TKTL1通过调节戊糖磷酸途径维持癌细胞存活。基于抗体靶向的干预策略在动物模型中显著抑制肿瘤生长，支持其用于开发靶向代谢的抗体药物。
---
**备注**：以上文献信息为示例，实际引用需核对具体来源及数据库(如PubMed、Web of Science)中的准确信息。
The TKTL1 (transketolase-like protein 1) antibody is a tool used to detect the expression of the TKTL1 protein, a member of the transketolase family involved in the pentose phosphate pathway (PPP). TKTL1 plays a critical role in cellular metabolism, particularly in cancer cells, where it is associated with enhanced aerobic glycolysis (Warburg effect) and NADPH production, supporting tumor growth under hypoxic conditions. Overexpression of TKTL1 has been linked to aggressive cancer progression, metastasis, and poor prognosis in various cancers, including colorectal, breast, and head-and-neck carcinomas.
TKTL1 antibodies are primarily utilized in research to investigate its metabolic contributions to oncogenesis and its potential as a diagnostic or therapeutic target. These antibodies enable the detection of TKTL1 in tissues or cell lines via techniques like immunohistochemistry, Western blotting, or ELISA. Notably, TKTL1’s homology with other transketolase family members (e.g., TKTL2) necessitates rigorous validation of antibody specificity to avoid cross-reactivity. Recent studies also explore TKTL1’s role in epigenetic regulation and drug resistance, expanding its relevance in precision oncology.
Despite its promise, challenges remain in standardizing TKTL1 detection across studies, partly due to variability in antibody performance and epitope recognition. Ongoing research aims to refine antibody-based assays and evaluate TKTL1 inhibition strategies, positioning it as a potential biomarker or target in cancer therapeutics.
×
